Detail akcie Macrogenics online

Business Summary: MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, MacroGenics Inc revenues decreased 61% to $58.7M. Net loss applicable to common stockholders decreased 92% to $9.1M. Revenues reflect Collaborative and other agreements decrease of 76% to $29M, Contract manufacturing decrease of 30% to $9.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.95 to -$0.15.